Medical Devices
All initial communications will be channeled through Flusso Capital to maintain a streamlined and effective investment process for all stakeholders.
MD248600
The $10.1B surgical robotics and guidance market is rapidly growing, yet surgeons still rely on limited visualization, manual navigation, and subjective decision-making, increasing the risk of complications and reoperations. This company is transforming the operating room with an AI-powered surgical guidance system that integrates real-time 3D mapping, advanced tissue recognition, and precision-enhancing automation to improve accuracy, efficiency, and patient outcomes.
Unlike traditional laparoscopic and robotic systems that offer limited intraoperative insights, this next-generation platform provides real-time AI-driven support, allowing surgeons to visualize critical structures, anticipate complications, and enhance surgical precision—drastically reducing the need for revisions and optimizing healthcare costs. With exclusive IP, partnerships with top-tier medical institutions, and a first-mover advantage in AI-assisted surgery, the company is positioned to disrupt the field of minimally invasive procedures.
Currently raising $3M to finalize product development, conduct hospital testing, and secure FDA clearance, this is a rare opportunity to invest in the future of AI-driven surgical innovation.
MD200982
The $1.8 trillion global pain management market is dominated by opioids and pharmaceuticals that often lead to dependency, side effects, and limited long-term effectiveness. Millions of people suffering from chronic pain lack accessible, drug-free alternatives, creating an urgent need for innovation in the field.
This company has developed a clinically validated, non-invasive neurotechnology that targets the brain’s maladaptive pain signals—providing measurable relief without medication. Unlike conventional treatments that mask symptoms, this AI-powered neurofeedback system rewires the brain’s pain response, offering a scalable, home-based solution that eliminates the need for costly clinic visits or pharmaceutical dependency.
With regulatory approvals secured in key markets including the US, UK, and New Zealand, strategic distribution partnerships, and a first-mover advantage in AI-driven pain management, the company is positioned to disrupt the industry and transform the standard of care.
Currently raising $10M to scale production, accelerate commercialization, and expand into adjacent markets like mental health, this is a high-impact opportunity to invest in the future of neurotechnology and digital therapeutics.
MD601024
Lung cancer is one of the most challenging diseases to diagnose early, with existing screening methods being expensive, invasive, and producing a high rate of false positives. Many cases go undetected until late stages, limiting treatment options and survival rates. There is a growing need for a cost-effective, accurate, and non-invasive diagnostic tool that enables earlier intervention.
This company has developed a breath-based cancer detection technology that identifies disease-specific biomarkers with high accuracy. Unlike traditional CT scans, which often lead to unnecessary procedures, this radiation-free, portable solution offers a more efficient way to screen large populations. By making early detection more accessible, it has the potential to improve patient outcomes and reduce healthcare costs.
With a strong intellectual property portfolio and a growing market demand for better screening solutions, the company is well-positioned to play a key role in the future of cancer diagnostics. Currently raising to advance clinical trials and regulatory approvals, this is an opportunity to invest in a company bringing much-needed innovation to early disease detection.
MD746398
The $117B remote patient monitoring market is expanding rapidly, yet traditional ultrasound imaging remains underutilized due to poor resolution, accessibility limitations, and reliance on expensive hardware. Many medical providers and researchers lack affordable, high-quality imaging solutions, creating an urgent need for a scalable, AI-enhanced alternative.
This company has developed an AI-driven imaging technology that enhances standard ultrasound devices, providing expert-level image resolution, tissue contrast, and real-time risk assessment without requiring new hardware. Unlike conventional imaging systems that are costly and confined to hospital settings, this technology enables high-quality remote diagnostics, preventive screening, and real-time monitoring—filling critical gaps in early disease detection and clinical research.
With clinical validation, industry partnerships, and a strong intellectual property portfolio, the company is positioned to drive significant advancements in AI-powered diagnostics. Currently raising to scale adoption, expand into pharmaceutical-driven imaging biomarkers, and accelerate deployment in telehealth and decentralized healthcare, this is an opportunity to invest in the future of AI-enabled medical imaging.
MD824598
The $30.8B brain imaging market is hindered by accessibility challenges, with traditional CT and MRI machines being expensive, stationary, and slow—leading to delayed diagnoses and poorer patient outcomes. This company is transforming neuroimaging with an AI-enhanced, portable brain scanner designed for both hospital and prehospital settings, enabling real-time diagnostics for stroke, traumatic brain injury, and other neurological conditions.
Unlike traditional imaging systems restricted to hospital use, this cost-effective, electromagnetic tomography-based device provides on-the-spot brain scans in emergency rooms, ambulances, and remote locations—ensuring faster intervention and improved patient management. The combination of AI-driven image enhancement and advanced sensor technology enables superior resolution, overcoming limitations of other portable solutions.
Currently raising to finalize clinical validation, regulatory approvals, and market expansion, this is a rare opportunity to invest in a game-changing neuroimaging technology poised to redefine emergency and critical care diagnostics worldwide.